ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY A. Maiolino; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS M. Dimopoulos; K. Weisel; P. Moreau; L.D.A. Jr; D. White; J.S. Miguel; P. Sonneveld; M. Engelhardt; M. Jenner; A. Corso; J. Dürig; M. Pavic; M. Salomo; E. Casal; R. Jiang; T. Nguyen; T. Peluso; P. Richardson;

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS M.E.Z. Capra; M. Beksac; P.G. Richardson; A. Unal; P. Corradini; S. Delimpasi; Z. Gulbas; G. Mikala; A. Neylon; A. Symeonidis; S. Bringhen; P. Moreau; H.V. Velde; F. Campana; S.L. Guennec; I. Spicka;